LTCA AND VENETO INSTITUTE OF ONCOLOGY AT ISCT 2020, PARIS

Redirecting CIK cell activity against CD19 positive B-cell malignancies as an alternative to CD19-CAR T cells

  • slide
  • slide
  • slide
LTCA and Istituto Oncologico Veneto to present their results on the development of an immunotherapy protocol against hematological malignancies based on the use of Citokine-Induced Killer Cells (CIK) "redirected" to recognize and to kill cancer cells.
More info here: